Deciphera Pharmaceuticals (NASDAQ:DCPH) Issues Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Deciphera Pharmaceuticals (NASDAQ:DCPHGet Rating) issued its quarterly earnings data on Thursday. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.05, Briefing.com reports. The business had revenue of $32.49 million for the quarter, compared to the consensus estimate of $30.11 million. Deciphera Pharmaceuticals had a negative return on equity of 79.96% and a negative net margin of 279.96%. The firm’s revenue was up 37.8% compared to the same quarter last year. During the same quarter last year, the business posted ($1.21) EPS.

Deciphera Pharmaceuticals Price Performance

Deciphera Pharmaceuticals stock traded down $0.30 during mid-day trading on Friday, reaching $16.51. 1,277,054 shares of the company were exchanged, compared to its average volume of 1,250,788. The firm has a market cap of $1.09 billion, a PE ratio of -3.38 and a beta of 1.11. The company has a fifty day simple moving average of $12.77 and a 200-day simple moving average of $10.49. Deciphera Pharmaceuticals has a 12 month low of $6.51 and a 12 month high of $17.20.

Institutional Trading of Deciphera Pharmaceuticals

Large investors have recently modified their holdings of the stock. Lazard Asset Management LLC acquired a new stake in shares of Deciphera Pharmaceuticals during the first quarter valued at about $57,000. Mariner LLC boosted its stake in shares of Deciphera Pharmaceuticals by 6.6% during the first quarter. Mariner LLC now owns 22,472 shares of the company’s stock valued at $208,000 after purchasing an additional 1,401 shares in the last quarter. MetLife Investment Management LLC boosted its stake in shares of Deciphera Pharmaceuticals by 55.0% during the first quarter. MetLife Investment Management LLC now owns 23,468 shares of the company’s stock valued at $218,000 after purchasing an additional 8,328 shares in the last quarter. BNP Paribas Arbitrage SA boosted its stake in shares of Deciphera Pharmaceuticals by 17.0% during the first quarter. BNP Paribas Arbitrage SA now owns 23,557 shares of the company’s stock valued at $218,000 after purchasing an additional 3,417 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of Deciphera Pharmaceuticals in the first quarter worth approximately $278,000. 87.97% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have issued reports on DCPH. JMP Securities raised Deciphera Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $23.00 price target on the stock in a research note on Friday. SVB Leerink lifted their price target on Deciphera Pharmaceuticals from $15.00 to $21.00 and gave the company an “outperform” rating in a research note on Friday. Finally, HC Wainwright lifted their target price on Deciphera Pharmaceuticals from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Friday. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, Deciphera Pharmaceuticals has an average rating of “Hold” and a consensus price target of $14.13.

About Deciphera Pharmaceuticals

(Get Rating)

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.

Recommended Stories

Earnings History for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.